NCT07312214 is a NA clinical trial of LED red light in Pathologic Myopia, sponsored by Shanghai Eye Disease Prevention and Treatment Center.

Who is sponsoring NCT07312214?

NCT07312214 is sponsored by Shanghai Eye Disease Prevention and Treatment Center.

What drugs are being tested in NCT07312214?

Interventions in NCT07312214: LED red light, Sham LED red light.

What condition does NCT07312214 study?

NCT07312214 studies Pathologic Myopia.

Is NCT07312214 still recruiting?

NCT07312214 is currently recruiting now. Last updated 31 December 2025.

Last reviewed 2025-12-31 · How we verify

NCT07312214

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

LED Red Light in Modulating Choroidal Microcirculation to Retard Retinal Atrophy in Pathological Myopia

Recruiting now NA Last updated 31 December 2025

What this trial tests

NA trial testing LED red light in Pathologic Myopia in 158 participants. Currently enrolling.

Timeline

31 December 2025

Primary endpoint
30 December 2028

30 December 2028

Quick facts

Lead sponsor	Shanghai Eye Disease Prevention and Treatment Center
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	158
Start date	31 December 2025
Primary completion	30 December 2028
Estimated completion	30 December 2028
Sites	1 location across China

Drugs / interventions tested

LED red light
Sham LED red light

Conditions studied

Pathologic Myopia — all drugs for Pathologic Myopia →

Sponsor

Shanghai Eye Disease Prevention and Treatment Center — full company profile →

Who can join

Adults 18 to 55, any sex, with Pathologic Myopia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to learn if repeated low-level red light (RLRL) therapy works to treat pathologic myopia in adults. It will also learn about the safety of RLRL. The main questions it aims to answer are: Does RLRL modulate choroidal microcirculation to retard retinal atrophy in pathological myopia? What medical problems do participants have when receiving RLRL therapy? Researchers will compare RLRL to a sham RLRL device (identical in appearance but delivering \<10% of the original device's energy output) to see if RLRL works to treat pathologic myopia. Participants will: Take RLRL or sham RLRL twice daily, 3 minutes per session, 5 days per week, for a total duration of 12 months. Visit the clinic once every 3 months for checkups and tests Keep a diary of their symptoms and their visual perception

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

LED red light for atrophy and microcirculation in pathologic myopia (RAMP): study design and protocol for a multicentre randomised controlled trial.
Zhang J, Yu J, Wang X, Sun T, et al · · 2026 · PMID 41942156 · DOI 10.1136/bmjopen-2026-117063

Verify or expand the search:

Other recruiting trials for Pathologic Myopia

Currently open trials in the same condition.

NCT06322433 — Follow up of High Myopic Eyes · recruiting

Other Shanghai Eye Disease Prevention and Treatment Center trials

Trials by the same sponsor.

NCT07535658 — Efficacy of Multi-Type Photolithography Flat Microstructure Lenses for Childhood Myopia Control · NA · not yet recruiting
NCT07514039 — Photolithography Microstructure Myopia Management Lenses in Preventing and Controlling Myopia in Children and Adolescent · NA · enrolling by invitation
NCT07120737 — Efficacy and Safety of Spectacle Lenses With H.A.L.T. MAX Technology on High Myopia Control in Children and Adolescents · NA · not yet recruiting
NCT07284147 — 3D Designed Defocus Lenses on Myopia Control in Children and Adolescents · NA · enrolling by invitation
NCT07176949 — Early-Onset Myopia Intervention Project · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07312214 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Eye Disease Prevention and Treatment Center
Last refreshed: 31 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07312214.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing